PRESS RELEASE

Results of 2022 Annual General Meeting

Guildford, 10 June 2022: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today.  All Resolutions were duly passed.

Details of the voting by way of a poll at the AGM in respect of each resolution are shown in the table below:

The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com

Ergomed's Board engage with the Company's shareholders and other stakeholders to understand their views. Whilst all resolutions were passed, shareholders representing over 20% of votes cast voted against Resolution 5 and the Board will re-engage with them to better understand their position.

ENDS

Enquiries:

Ergomed plc                                                                           Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)      

Richard Barfield (Chief Financial Officer)           

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis                                                                                      Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)      

James Black (Broker)   

Peel Hunt LLP                                                                          Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

Consilium Strategic Communications                                      Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal                                                     [email protected]

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.